Cancer biosimilar drug Pelgraz is poised to hit the market after receiving a positive opinion by the Committee for Medicinal Products for Human Use (CHMP).
Already facing competition from Sandoz, Amgen’s Neupogen white blood cell stimulator faces another cut-price near-copy after the FDA approved Pfizer’s biosimilar, Nivestym.
